Zoticon, an Israel-based medical organization, invests in late-stage therapeutics, creating dedicated companies for focused drug development.
50
Operating
Rehovot, Central District, IL
Founded in Rehovot, Central District, Israel, Zoticon BioVentures is a medical organization dedicated to investing in late-stage therapeutics. With a core mission to bring innovative drugs to patients, Zoticon focuses on phase III therapeutics, particularly in oncology and cardiovascular treatments. The company creates a new entity for each in-licensed asset, ensuring specialized and concentrated development efforts. Zoticon's vision is to advance medical treatments through strategic investments and dedicated development processes.
Zoticon has invested over $100 million to date, backed by solid financial institutions that share its commitment to medical innovation. Notable affiliated individuals include experienced professionals in the pharmaceutical and biotech industries. The company's key achievements include advancing two oncology products and a cardiovascular combination product through late-stage development. Zoticon's impact lies in its ability to bring promising therapeutics closer to market, potentially improving patient outcomes and contributing to medical advancements.
Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
Portfolio Companies1
Follow-on Investments2
Total Portfolio Exits1
Top Investment Stages
Series C1 (50.0%)
Series D1 (50.0%)
Stage Mix
Series C 50%Series D 50%
Concentration shown as share of disclosed investments by stage.
